BCANTT 2020: BCG Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer

(UroToday.com) Peter Black, MD, of Vancouver Prostate Center and the University of British Columbia, presented a thorough discussion regarding bacillus calmette-guerin (BCG) unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). The consensus definition which was established and used by the Food and Drug Administration (FDA) which are important for clinical trials but also translational scientists which can more accurately determine which patients are BCG unresponsive. This is important as radical cystectomy is the guideline recommendation for BCG unresponsive disease. Bladder sparing treatments have been limited and recently investigated agents have and are being tested in clinical trials. He presented retrospective data regarding gemcitabine/docetaxel for BCG-unresponsive disease. Against this backdrop, he discussed recent clinical trials and future direction. 



Presented by: Peter Black, MD, Vancouver Prostate Center and the University of British Columbia, Vancouver, British Columbia, Canada

Written by: Stephen B. Williams, MD, Medical Director for High-Value Care; Chief of Urology, Professor, Director of Urologic Oncology, Director Urologic Research, The University of Texas Medical Branch at Galveston, TX at the 2020 Virtual Bladder Cancer Advocacy Network Think Tank 2020

Related Content: 
Read: BCANTT 2020: Non-Muscle Invasive BCG Unresponsive Bladder Cancer
Watch: A Debate on The Management of BCG Unresponsive - Cystectomy Ineligible Bladder Cancer Patient: Pembrolizumab Vs. Nadofaragene Firadenovec - Arjun Balar & Peter Black
Watch: How to Define Treatment Failure After BCG Treatment for Nonmuscle-Invasive Bladder Cancer - Peter Black